Polypill

BP control is an important part of CVD prevention, but better evidence is needed, as is more tailored outreach to at-risk populations, a speaker said at the American Society for Preventive Cardiology Congress on CVD Prevention.

Adults at intermediate CV risk assigned a polypill plus aspirin were 31% less likely to experience a CV event or death compared with those assigned double placebo over a nearly 5-year period, according to new data from the TIPS-3 trial.

Trials of novel medications and conversations on systemic racism and the ongoing COVID-19 pandemic are set to be featured at the virtual American Heart Association Scientific Sessions, which start Friday.